Research Topic

mTOR and ERK Kinase Signaling Pathways in Renal Cell Carcinoma

About this Research Topic

The mammalian target of rapamycin (mTOR) as well as extracellular signal-regulated kinases (ERKs) are protein kinases that regulate signaling pathways involved in cellular metabolism, proliferation and differentiation. Both mTOR and ERK are serine-threonine kinases that represent a central point for the regulation of different biological processes including cell cycle, apoptosis, autophagy and protein synthesis. ERK kinases belong to the mitogen-activated protein kinases (MAPK) while mTOR is associated with the phosphoinositide 3-kinase (PI3K) kinase family. The dysregulation of mTOR and ERK signaling leads to the development of different diseases including cancer. In kidney carcinoma, inactivation of the VHL gene induces hyperactivation of the hypoxia-inducible factor (HIF), increasing the activity of ERK, mTOR and NF-κB signalling pathways that, in turn, contribute to cancer progression.

Renal cell carcinoma (RCC) is the most common kidney cancer representing about 3% of all types of human tumors. One third of RCC subjects develop metastases that are difficult to treat causing high mortality in RCC patients. The main treatment for patients with metastatic RCC is represented by the use of tyrosine kinase inhibitors (TKIs) and mTOR blockers. However, the treatment of advanced RCC with these inhibitors has shown limited success, since RCC patients develop resistance to cancer therapy. Many signaling pathways are dysregulated in RCC, including mTOR and ERK kinases that modulate cell proliferation, migration, apoptosis, autophagy and other biological processes, contributing to cancer progression. The goal of this research field is the study of molecules involved in kidney cancer, in particular, mTOR and ERK signalling pathways as well as possible new players, that may form a cancer network in RCC. The discovery of new elements associated with RCC could lead to the detection of new therapeutic targets for RCC treatment that could improve the overall survival and quality of life of metastatic RCC patients.

The aim of this Research Topic is to highlight significant scientific improvements in the research addressed to investigate the role of mTOR and ERK kinases in RCC. We welcome Original Research, Reviews, Methods and Opinion articles on the following topics:

• mTOR and ERK signaling in RCC development and progression
• mTOR and ERK function in cell growth and migration
• Autophagy and RCC: role of mTOR
• mTOR, ERK and HIF network for cell cycle and apoptosis regulation
• Targeting of signaling pathways driven by mTOR and ERK for RCC treatment


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

The mammalian target of rapamycin (mTOR) as well as extracellular signal-regulated kinases (ERKs) are protein kinases that regulate signaling pathways involved in cellular metabolism, proliferation and differentiation. Both mTOR and ERK are serine-threonine kinases that represent a central point for the regulation of different biological processes including cell cycle, apoptosis, autophagy and protein synthesis. ERK kinases belong to the mitogen-activated protein kinases (MAPK) while mTOR is associated with the phosphoinositide 3-kinase (PI3K) kinase family. The dysregulation of mTOR and ERK signaling leads to the development of different diseases including cancer. In kidney carcinoma, inactivation of the VHL gene induces hyperactivation of the hypoxia-inducible factor (HIF), increasing the activity of ERK, mTOR and NF-κB signalling pathways that, in turn, contribute to cancer progression.

Renal cell carcinoma (RCC) is the most common kidney cancer representing about 3% of all types of human tumors. One third of RCC subjects develop metastases that are difficult to treat causing high mortality in RCC patients. The main treatment for patients with metastatic RCC is represented by the use of tyrosine kinase inhibitors (TKIs) and mTOR blockers. However, the treatment of advanced RCC with these inhibitors has shown limited success, since RCC patients develop resistance to cancer therapy. Many signaling pathways are dysregulated in RCC, including mTOR and ERK kinases that modulate cell proliferation, migration, apoptosis, autophagy and other biological processes, contributing to cancer progression. The goal of this research field is the study of molecules involved in kidney cancer, in particular, mTOR and ERK signalling pathways as well as possible new players, that may form a cancer network in RCC. The discovery of new elements associated with RCC could lead to the detection of new therapeutic targets for RCC treatment that could improve the overall survival and quality of life of metastatic RCC patients.

The aim of this Research Topic is to highlight significant scientific improvements in the research addressed to investigate the role of mTOR and ERK kinases in RCC. We welcome Original Research, Reviews, Methods and Opinion articles on the following topics:

• mTOR and ERK signaling in RCC development and progression
• mTOR and ERK function in cell growth and migration
• Autophagy and RCC: role of mTOR
• mTOR, ERK and HIF network for cell cycle and apoptosis regulation
• Targeting of signaling pathways driven by mTOR and ERK for RCC treatment


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

16 June 2020 Abstract
01 September 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

16 June 2020 Abstract
01 September 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..